Weekly FDA Roundup: GLP-1 Crackdown, Abbott's Triple Hit, and the Artificial Colors Pivot — Week of Jan 31–Feb 7, 2026

This week, FDA moved from warning to action on GLP-1 compounding, delivered a three-punch combination to Abbott's diabetes care division, and signaled a sweeping shift away from petroleum-based food dyes — all while processing 60 regulatory actions including 25 recalls, 11 warning letters, and 9 safety alerts.

By the Numbers

• 60 total actions for the week of Jan 31–Feb 7, 2026
• 25 recalls — 2 Class I (immediate health risk), 20 Class II, 1 Class III, 2 unclassified
• 11 warning letters — spanning medical devices, pharma, dietary supplements, tobacco, and seafood
• 9 safety alerts — including two Class I medical device recalls
• 3 press releases — GLP-1 enforcement intent, artificial color policy shift, and PreCheck pilot launch
• Key substances: Listeria monocytogenes (12 recall actions), Salmonella Typhimurium (2 Class I recalls), semaglutide/tirzepatide (dominant theme in enforcement context)

---

Lead Story: FDA Signals the End of the GLP-1 Compounding Era

On February 6, FDA issued a press release with a direct message: the agency intends to take decisive action against non-FDA-approved GLP-1 active pharmaceutical ingredients in compounded drugs.

The announcement marks a significant escalation. For the past two years, compounding pharmacies operated under a legal carve-out: when FDA-approved semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were in short supply, compounders could legally produce alternatives under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. FDA has since declared both drug shortages resolved, eliminating the legal basis for large-scale compounding — but many telehealth platforms kept marketing and selling compounded GLP-1 products anyway.

This week's announcement names the mechanism: FDA intends to restrict the use of non-approved GLP-1 APIs in compounding, targeting formulations that effectively circumvent the drug approval process. The enforcement signal is blunt. "Compounded drugs can be important for overcoming shortages or meeting unique patient needs — but compounders should not try to compound drugs in a way that circumvents FDA's approval process," said FDA Commissioner Marty Makary.

The downstream effects are already materializing. Within days of the announcement, Novo Nordisk filed patent infringement suits against major telehealth GLP-1 compounders, and FDA followed up in early March with 30 warning letters to telehealth companies for false and misleading GLP-1 marketing claims — including to companies operated by public figures.

---

Key Developments

Abbott Diabetes Care Takes a Three-Hit Combination

This week was bruising for Abbott Diabetes Care. Three separate enforcement actions landed in the same 48-hour window.

First, on February 3, FDA issued a warning letter to Abbott Diabetes Care's Alameda, CA facility for significant quality management system (QMS) violations — the company failed to adequately investigate complaints and correct identified problems. Then on the same day, FDA issued a warning letter to Flextronics America LLC, Abbott's contract manufacturer for Continuous Glucose Monitors, for parallel QMS failures. Two days later, on February 5, FDA posted a Class I recall of certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus CGM sensors — the most serious classification, reserved for products where use could cause serious health consequences.

The combination of warning letters targeting both manufacturer and contract manufacturer, followed by a Class I recall, suggests the underlying quality failures were systemic rather than isolated. Class II device manufacturers with CGM products or outsourced manufacturing relationships should treat this as a direct signal: FDA is examining the full supply chain, not just the name on the label.

FDA Shifts Policy on "No Artificial Colors" Claims

On February 5, FDA announced a new policy on "No Artificial Colors" labeling claims, allowing food companies to use this language on products that contain no petroleum-based synthetic dyes. The policy formalizes what has been an industry-driven marketing move and provides regulatory clarity for manufacturers navigating the transition away from FD&C synthetic dyes.

This was paired with two final rules published on February 6: FDA amended 21 CFR Part 73 to officially list Beetroot Red and Spirulina Extract as color additives exempt from batch certification — effective March 23, 2026. Both moves align with the Trump administration's broader MAHA initiative to phase out petroleum-based food dyes by end of 2026.

Food manufacturers with products currently using FD&C Red 40, Yellow 5, Yellow 6, or Blue 1/2 have a regulatory runway, but the policy direction is unambiguous: reformulate or prepare for future restrictions.

Prima Vera Nueva: One Manufacturer, Ten Listeria Recalls

Prima Vera Nueva, Inc. (also operating as Primavera) triggered one of the more striking single-company recall events this week: ten distinct Class II recall actions on February 4, all for the same root cause — potential contamination with Listeria monocytogenes across their entire refrigerated tamale product line.

The recalled SKUs span every variant in their lineup: Black Bean Bonanza, BBQ Chipotle Bean & White Cheddar, Roasted Green Chile, Roasted Pumpkin & White Cheddar, Butternut Squash, Mushroom Spinach & Salsa — both dairy and dairy-free versions. The breadth of the recall suggests contamination at a shared ingredient or production step rather than an isolated lot issue.

For manufacturers of refrigerated ready-to-eat products, particularly those with multiple SKUs sharing common processing lines: this pattern — one pathogen, one facility, ten products — is the textbook outcome of an unresolved environmental Listeria problem.

Live It Up Super Greens: Class I Recall for Salmonella in Dietary Supplements

Superfoods, Inc. recalled two SKUs of Live it Up brand Super Greens powder on February 4 at Class I classification for potential contamination with Salmonella Typhimurium. The affected products — Natural Wild Berry and unflavored varieties containing chlorella, spirulina, wheatgrass, kale, and broccoli — were distributed nationally.

Class I supplement recalls for pathogenic bacteria remain relatively uncommon but consistently high-impact. For dietary supplement manufacturers using botanical ingredient blends from multiple suppliers, this is a reminder that certificate-of-analysis testing from suppliers is not sufficient — finished product pathogen testing is the only reliable backstop.

CGMP Enforcement: 11 Warning Letters in One Week

The week's warning letter volume — 11 letters, all posted February 3 — swept across sectors:

• Cohance Lifesciences Limited (India): Drug CGMP violations at a generic drug API/finished dose manufacturer. Indian pharmaceutical exporters continue to draw disproportionate FDA scrutiny — this follows a pattern that has generated more than 85 CGMP-related actions in the current 60-day window.
• Eniva USA, Inc. and CC Pollen Company: Dietary supplement CGMP violations under 21 CFR Part 111. Both companies in the botanicals/herbal and specialty supplement categories.
• HTO Nevada, Inc. dba Kirkman: OTC drug CGMP violations at its Lake Oswego, OR facility.
• Unomedical Device S.A. de C.V.: Quality system violations at the insulin infusion set manufacturer.
• gotpouches.com: Marketing unauthorized nicotine pouch products without required premarket authorization.

FDA PreCheck Pilot: A New Model for Domestic Manufacturing Oversight

On February 1, FDA launched the PreCheck pilot program to strengthen the domestic pharmaceutical supply chain. The initiative offers manufacturers increased regulatory predictability in exchange for higher transparency and quality system commitments — essentially a tiered inspection model that rewards demonstrated compliance with less friction.

For domestic drug manufacturers considering whether to participate: the early-mover advantage is real. Companies that establish a track record under PreCheck before it scales will have credibility with FDA that late adopters won't.

---

The Bigger Picture

The GLP-1 crackdown isn't a discrete enforcement event — it's the culmination of a regulatory squeeze that has been building since late 2025. In the 60 days prior to this week, FDA generated 29 semaglutide-related actions and 27 tirzepatide-related actions, plus 38 items in the compounded drugs product category. That volume reflects FDA working through the queue of enforcement referrals that accumulated during the shortage period.

What this week's press release adds is institutional signal: FDA is now willing to restrict the APIs themselves, not just the marketing claims around them. That shifts the exposure profile for compounders from "advertising risk" to "product existence risk."

The artificial colors policy shift tells a parallel story. The back-to-back approvals of Beetroot Red and Spirulina Extract as certified-exempt colorants, paired with the "No Artificial Colors" claims policy, give manufacturers the regulatory infrastructure to make the transition. FDA is doing the enabling work before the enforcement work.

---

What to Watch

• GLP-1 enforcement escalation: The February 6 announcement signals more formal actions — expect warning letters, import alerts, or injunctions targeting API suppliers and large-scale compounders. FDA's stated enforcement targets are non-FDA-approved APIs used to circumvent the drug approval process.
• FD&C dye phase-out timeline: With Beetroot Red and Spirulina Extract now approved and the "No Artificial Colors" policy clarified, watch for FDA to issue further guidance — or enforcement — on manufacturers still relying on petroleum-based dyes past the informal 2026 target date.
• Abbott FreeStyle Libre 3 Class I recall scope: The February 5 safety alert is an early signal; watch for an expanded recall notice specifying affected lot numbers and distribution scope.
• Indian pharma CGMP scrutiny: Cohance Lifesciences is the latest in a sustained pattern. Companies sourcing APIs or finished dosage forms from Indian manufacturers should audit their supplier qualification documentation.

---

Policy Canary monitors FDA changes for your specific products — by name, by ingredient. Join the pilot program.